Explore Chief Executive, The European, and more!

Explore related topics

AstraZeneca Plc Chief Executive Officer Pascal Soriot said the lack of progress in negotiations between the U.K. and the European Union on their future ties is worrying, and could hinder the drugmaker’s exports to foreign markets after Brexit.

Astra's Soriot Says Slow Pace of Brexit Talks an Area of Concern

AstraZeneca Plc Chief Executive Officer Pascal Soriot said the lack of progress in negotiations between the U. and the European Union on their future ties is worrying, and could hinder the drugmaker’s exports to foreign markets after Brexit.

Nearly seven months into the job, GlaxoSmithKline's (GSK.L) new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain's biggest drugmaker.

GlaxoSmithKline's new boss struggles to sell cure for drugmaker

Nearly seven months into the job, GlaxoSmithKline's (GSK.L) new chief executive is facing a battle to convince investors she has the right prescription for growth at Britain's biggest drugmaker.

The SuperStar Pet Services Report: Beagle Freedom Project wants to bring Beagles used for research to California. Pharma giant AstroZeneca says NO. These little guys need our help. Call or write AstraZeneca and help the Hounds

Largest public school education system Cal State University to offer online degrees. But cost may be prohibitive says Dean Florez, president and CEO of 20 Million Minds.

Three Reasons You Should Use Google+ In Your Business - http://www.forbes.com/sites/ciocentral/2012/03/02/three-reasons-you-should-use-google-in-your-business/

Three Reasons You Should Use Google+ In Your Business

Anis Uzzaman and Tom Maxim described the startup investment opportunities in Singapore, Japan, and Indonesia, July 2013

GlaxoSmithKline's (GSK.L) former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, following a route favored by many ex-pharma executives.

Former GSK CEO and ex-R&D boss move to biotech venture firms

GlaxoSmithKline's (GSK.L) former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, following a route favored by many ex-pharma executives.

Companies can drop prices and still make money, says the chief executive of GlaxoSmithKline.

The Pharma C.E.O. Who Wants to Lower Drug Prices

Roche is convinced a new breast cancer drug will have a significant role in treating the disease despite recent trial results that disappointed analysts, the Swiss drugmaker's chief executive said in an interview published on Sunday.

Roche CEO still optimistic on new breast cancer drug

announces positive results for Actemra in phase III study - Reuters: Reuters Roche announces positive results for Actemra in phase…

Johnson & Johnson Chief Executive Alex Gorsky participates in a panel discussion during the White...

Johnson & Johnson Looks to Expand in Asia

Johnson & Johnson backs out negotiations to buy Actelion Pharmaceuticals

Never leave a child alone during a meltdown - Child In Mind - Boston.com

Never leave a child alone during a meltdown - Child in Mind

Pinterest
Search